An update from Avalo Therapeutics (AVTX) is now available.
Avalo Therapeutics has appointed Dr. Mittie Doyle as its new Chief Medical Officer, bringing her over 20 years of pharmaceutical and biotech industry experience to the role. With a track record of leading clinical development and achieving global regulatory approvals, Dr. Doyle’s expertise will be a significant asset to Avalo’s executive team. To incentivize her appointment, Avalo has offered Dr. Doyle a $500,000 base salary along with a potential 40% bonus and a stock option grant, with terms including severance benefits and post-employment restrictions.
See more insights into AVTX stock on TipRanks’ Stock Analysis page.
